Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat Commun. 2018 12 05; 9(1):5200.
View in:
PubMed
subject areas
Acetylation
Animals
Breast Neoplasms
Cell Cycle Proteins
Cell Line, Tumor
Cell Nucleus
Cyclin-Dependent Kinase 6
Female
Forkhead Box Protein O3
Gene Expression Regulation
Heterocyclic Compounds, 3-Ring
Humans
Mice
Mice, Nude
Nuclear Proteins
Oxadiazoles
Promoter Regions, Genetic
Protein Binding
Protein Domains
Protein Kinase Inhibitors
Protein Transport
Proto-Oncogene Proteins c-akt
Pyrimidines
Pyrroles
Sirtuins
Transcription Factors
authors with profiles
Bin Zhou